The 2025 update of the ELN-DAVID MRD guideline harmonizes MRD assessment for each AML subtype facilitating consistent technical and clinical use.

Please click here for the publication.

Reference:

Cloos J, Valk PJM, Thiede C, Döhner K, Roboz GJ, Wood BL, Walter RB, Wang SA, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw DC, Kern W, Kim DDHDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bücklein VL, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon RJ, Heuser M. (2025): Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood, blood.2025031480. doi: 10.1182/blood.2025031480. PMID: 41397238